Zoligratinib

Zoligratinib (Debio 1347) is an orally available and selective FGFR inhibitor with IC50s of 9.3, 7.6, and 22 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.

Product Specifications

CAS Number

[1265229-25-1]

Product Name Alternative

Debio 1347; CH5183284

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

FGFR

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/CH5183284.html

Purity

99.76

Solubility

DMSO : 25 mg/mL (ultrasonic; warming; heat to 50°C)

Smiles

O=C(C1=C(N)N(C2=CC=C3N=C(C)NC3=C2)N=C1)C(N4)=CC5=C4C=CC=C5

Molecular Formula

C20H16N6O

Molecular Weight

356.38

Precautions

H302, H315, H319, H335

References & Citations

[1]Nakanishi Y, et al. The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor. Mol Cancer Ther. 2014 Nov;13 (11) :2547-58.|[2]Nakanishi Y, et al. Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1. Mol Cancer Ther. 2015 Mar;14 (3) :704-12.|[3]Nakanishi Y, et al. ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor. Mol Cancer Ther. 2015 Dec;14 (12) :2831-9.